R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine,General Medicine
Reference80 articles.
1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes;Teras;CA Cancer J Clin,2016
2. Chinese guidelines for diagnosis and treatment of diffuse large B cell lymphoma (in Chinese);Chin J Hematol,2013
3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte;Coiffier;Blood,2010
4. Three-year follow-up on the safety and effectiveness of rituximab plus chemotherapy as first-line treatment of diffuse large B-cell lymphoma and follicular lymphoma in real-world clinical settings in China: A prospective, multicenter, noninterventional study;Wu;Chin Med J,2018
5. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study;Crump;Blood,2017
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma;Scientific Reports;2024-09-11
2. Drug resistance in human cancers — Mechanisms and implications;Life Sciences;2024-09
3. NEAT1 and CHROMR lncRNAs: a promising diagnostic tool for diffuse large B-cell lymphoma especially in elderly patients;Biomarkers in Medicine;2024-08-17
4. A comprehensive prognostic and immune infiltration analysis of UBA1 in pan‐cancer: A computational analysis and in vitro experiments;Journal of Cellular and Molecular Medicine;2024-08
5. Network Pharmacology, Molecular Docking, and Experimental Validation of the Mechanism of Jiedu Xiaoliu Formula against Diffuse Large B-Cell Lymphoma;Combinatorial Chemistry & High Throughput Screening;2024-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3